TD Asset Management
RCUS icon

TD Asset Management’s Arcus Biosciences RCUS Stock Holding History

TD Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,500
Closed -$477K – 1441
2023
Q2 		$477K Buy
23,500
+8,100
+53% +$154K ﹤0.01% 1276
2023
Q1 		$281K Sell
15,400
-46,900
-75% -$896K ﹤0.01% 1348
2022
Q4 		$1.29M Buy
+62,300
New +$1.71M ﹤0.01% 1097
2019
Q1 		– Sell
-20,758
Closed -$224K – 1385
2018
Q4 		$224K Sell
20,758
-2,003
-9% -$23.4K ﹤0.01% 1342
2018
Q3 		$317K Sell
22,761
-6,497
-22% -$82.9K ﹤0.01% 1362
2018
Q2 		$358K Hold
29,258
– – ﹤0.01% 1334
2018
Q1 		$452K Buy
+29,258
New +$487K ﹤0.01% 1223

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TD Asset Management's RCUS Position: Q3 2023 in Review

TD Asset Management sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 23,500 shares — an estimated $477K sold.

TD Asset Management first reported a position in RCUS in Q1 2018 and held it in 7 quarters. The position peaked at $1.29M in Q4 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

  • TD Asset Management reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
  • TD Asset Management sold 23,500 Arcus Biosciences shares in Q3 2023, an estimated $477K.
  • TD Asset Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 7 quarters.
  • TD Asset Management's Arcus Biosciences position peaked at $1.29M in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.